Mahaney Paige 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics CSO Paige Mahaney Receives 240,000-Share RSU Award
What Happened
- Paige Mahaney, Chief Scientific Officer of C4 Therapeutics (CCCC), was granted 240,000 restricted stock units (RSUs) on Feb 13, 2026 (award code A). Those RSUs were reported at $0.00 per share (typical for RSU grants). Separately, on Feb 14, 2026 the filing reports the acquisition/conversion of 7,050 shares (transaction code M) related to vesting/conversion of a previously disclosed RSU grant. To satisfy tax withholding obligations, 2,446 shares were withheld/disposed at $1.89 per share for a withholding value of $4,623; this withholding is not a market sale.
Key Details
- Transaction dates and amounts:
- 2026-02-13: Grant of 240,000 RSUs (code A) — $0.00 per share.
- 2026-02-14: Conversion/acquisition of 7,050 shares (code M) — $0.00 per share (reflects vesting/settlement of an earlier RSU grant).
- 2026-02-14: 2,446 shares withheld for tax obligations (code F) at $1.89 = $4,623 (not a sale).
- Shares owned following the reported transactions: not specified in the filing.
- Footnotes of note:
- F1: The 240,000 RSUs vest per schedule — 120,000 vest in three equal annual installments starting Feb 13, 2027; the other 120,000 vest in full on Feb 13, 2029, subject to performance-based acceleration.
- F2: The 7,050-share acquisition reflects vesting/settlement of a previously disclosed RSU grant (originally reported Feb 18, 2025).
- F3: The 2,446-share disposition is withholding to cover taxes and does not represent a market sale by the insider.
- Filing date: Form 4 filed Feb 18, 2026. The filing covers transactions dated Feb 13–14, 2026; the filing’s timeliness is as reported on the SEC submission.
Context
- These transactions are mostly grant/vesting-related (RSUs), not open-market purchases or opportunistic sales. RSU grants and routine tax-withholding are common compensation events and do not, by themselves, signal a buying or selling decision by the insider.
- For derivative entries: the M-code here denotes conversion/acquisition upon vesting of previously granted RSUs (no cash exercise price was reported).
Insider Transaction Report
Form 4
Mahaney Paige
Chief Scientific Officer
Transactions
- Award
Common Stock
[F1]2026-02-13+240,000→ 339,356 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+7,050→ 339,356 total - Tax Payment
Common Stock
[F3]2026-02-14$1.89/sh−2,446$4,623→ 336,910 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Signature
/s/ Shagha Russell, Attorney-in-Fact|2026-02-18